Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

Shenton Research

Shenton Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Index Rebalance

<ul>
<li>MS-China adds 33 names and deletes 32, effective 1 Sep 2026. The ADDs include 31 A-shares and 2 HK stocks, the DELETEs 25 and 7.</li>
<li>Our ADD Hit rate was 15 of 16 announced (94%), with 1 false positive in 16 calls. DELETE Hit rate was 9 of 12 (75%).</li>
<li>All announced 33 ADDs enter the bridge after a +20.3% average run. We won't chase gap-ups.</li>
</ul>


MS-China adds 33 names and deletes 32, effective 1 Sep 2026. The ADDs include 31 A-shares and 2 HK stocks, the DELETEs 25 and 7.
Our ADD Hit rate was 15 of 16 announced (94%), with 1 false positive in 16 calls. DELETE Hit rate was 9 of 12 (75%).
All announced 33 ADDs enter the bridge after a +20.3% average run. We won't chase gap-ups.


China National Building Material (3323 HK)

BAIC BluePark New Energy Techn (600733 CH)

Hebei Changshan Biochemical Pharm (300255 CH)

Zhenjiang Dngfng Elctc Htg Techgy (300217 CH)

Nanya New Material Technology (688519 CH)

MS-China Sep 2026 Index Rebalance: Post-Announcement Positioning

Z.AI

MS-China Sep 2026 Index Rebalance: Post-Announcement Positioning